Equities

Hbm Holdings Ltd

Hbm Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.25
  • Today's Change0.07 / 5.93%
  • Shares traded984.00k
  • 1 Year change-35.23%
  • Beta2.1106
Data delayed at least 15 minutes, as of May 02 2024 04:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.

  • Revenue in HKD (TTM)700.32m
  • Net income in HKD178.38m
  • Incorporated2016
  • Employees154.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genor Biopharma Holdings Ltd0.00-729.64m640.67m104.00--0.4932-----1.44-1.440.002.530.000.00--0.00-37.91-55.46-44.02-63.73--66.56---14,819.185.38--0.006---100.00--7.65------
Pak Fah Yeow International Ltd259.16m105.04m651.33m102.006.200.85125.792.510.3370.3370.83162.460.29952.8822.182,540,765.0012.143.9912.604.1884.4580.7940.5321.276.9010.080.0062100.6876.0612.94250.6623.0218.83-8.06
Lee's Pharmaceutical Holdings Ltd1.05bn16.70m653.61m1.06k39.140.32063.860.62070.02840.02841.793.460.37131.8310.75996,247.900.703313.330.8817.7652.3561.921.8936.200.55263.900.09433.59-14.61-1.53-67.44-47.49-12.19-31.34
Fusen Pharmaceutical Co Ltd611.97m-39.25m667.46m1.15k--1.0918.531.09-0.0526-0.05260.81370.81340.41991.954.47533,076.30-2.690.9678-5.541.7452.9551.95-6.422.590.60960.710.3797--15.024.13-4.83------
Antengene Corporation Ltd72.82m-628.82m688.39m201.00--0.5545--9.45-1.02-1.020.11841.840.03580.97733.41362,298.90-30.91-53.57-36.46-58.9481.74---863.51-1,987.016.43--0.1491---57.97--3.38------
Jbm (Healthcare) Ltd610.30m97.99m725.41m258.008.010.77354.881.190.10870.10870.67861.120.44065.884.102,000,994.007.563.339.044.9347.7045.9717.1710.971.4522.150.121113.8128.1114.51131.906.14-5.09--
JW (Cayman) Therapeutics Co Ltd188.11m-830.95m741.70m398.00--0.4052--3.94-2.02-2.020.45714.420.07041.6865.54472,631.20-31.11-39.77-35.21-44.0050.74---441.74-1,316.813.86-47.820.1592--19.32--9.23---19.87--
Transcenta Holding Limited58.26m-500.49m789.84m215.00--0.7085--13.56-1.23-1.230.14312.550.02812.051.49270,991.00-24.17---33.97--26.74---859.01--1.20-32.870.285---47.15---13.72------
Zhaoke Ophthalmology Ltd20.29m-416.60m857.44m313.00--0.3869--42.27-0.7659-0.76590.03734.060.0075--0.343364,814.57-15.43---17.27--75.98---2,053.54--5.32-47.540.1041------5.47------
Hbm Holdings Ltd700.32m178.38m908.88m154.004.730.96584.241.300.24950.24950.96951.220.38863.903.014,547,516.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61------
Brii Biosciences Ltd667.58k-189.16m912.05m128.00--0.2702--1,366.21-0.26-0.260.00094.630.0002----5,215.44-5.60---5.84-------29,881.69------0.001---98.80--63.90------
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd910.53m160.36m918.81m848.005.730.57367.481.010.28620.28621.632.860.35872.182.941,073,735.006.327.679.1210.4869.4078.7917.6120.681.51--0.05157.22-0.00495.38-23.43-1.67-1.14--
Zhongzhi Pharmaceutical Holdings Ltd2.22bn176.12m993.14m2.64k5.530.87543.450.44780.20790.20792.621.311.122.5310.54839,136.508.957.6914.1511.7559.7360.568.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
CStone Pharmaceuticals501.86m-397.34m1.13bn230.00--2.29--2.25-0.315-0.3150.39730.38490.28112.443.722,182,016.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Jacobson Pharma Corporation Ltd1.68bn212.16m1.14bn1.59k5.120.47792.880.67740.11120.14090.88221.190.37222.877.50940,829.505.164.916.616.6042.0541.8113.8514.321.015.620.364635.9711.912.8941.304.42-6.226.39
VIVA Biotech Holdings2.33bn-125.63m1.15bn2.08k--0.28459.460.4912-0.0639-0.06391.201.860.28054.845.131,122,905.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.150.0350.3412---9.4259.3178.03------
Data as of May 02 2024. Currency figures normalised to Hbm Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

1.18%Per cent of shares held by top holders
HolderShares% Held
Bosera Asset Management Co., Ltd.as of 31 Dec 20224.79m0.62%
Dimensional Fund Advisors LPas of 04 Apr 20242.91m0.38%
SSgA Funds Management, Inc.as of 04 Apr 20241.28m0.17%
China Universal Asset Management Co., Ltd.as of 31 Dec 202280.00k0.01%
Dimensional Fund Advisors Ltd.as of 29 Feb 202441.92k0.01%
DFA Australia Ltd.as of 31 Dec 20233.59k0.00%
E Fund Management Co., Ltd.as of 30 Jun 20230.000.00%
Golden Eagle Asset Management Co., Ltd.as of 30 Jun 20230.000.00%
More ▼
Data from 30 Jun 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.